Aclaris Therapeutics Inc.'s video advertisement for the seborrheic keratoses drug Eskata (hydrogen peroxide) drew a reprimand from the US Food and Drug Administration for failing to include risk information and misrepresenting the efficacy of the treatment.
The video features an interview with a physician, identified as a paid spokesperson for Aclaris, who makes claims about the drug that are accompanied by side-by-side images of two patients before and after treatment with Eskata
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?